NO308740B1 - Kinazolinderivater, anvendelse derav og farmasøytisk blanding - Google Patents
Kinazolinderivater, anvendelse derav og farmasøytisk blandingInfo
- Publication number
- NO308740B1 NO308740B1 NO961299A NO961299A NO308740B1 NO 308740 B1 NO308740 B1 NO 308740B1 NO 961299 A NO961299 A NO 961299A NO 961299 A NO961299 A NO 961299A NO 308740 B1 NO308740 B1 NO 308740B1
- Authority
- NO
- Norway
- Prior art keywords
- quinazoline derivatives
- pharmaceutical admixture
- admixture
- pharmaceutical
- quinazoline
- Prior art date
Links
- 125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41330095A | 1995-03-30 | 1995-03-30 | |
PCT/IB1995/000436 WO1996030347A1 (fr) | 1995-03-30 | 1995-06-06 | Derives de quinazoline |
Publications (3)
Publication Number | Publication Date |
---|---|
NO961299D0 NO961299D0 (no) | 1996-03-29 |
NO961299L NO961299L (no) | 1996-10-01 |
NO308740B1 true NO308740B1 (no) | 2000-10-23 |
Family
ID=23636708
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO961299A NO308740B1 (no) | 1995-03-30 | 1996-03-29 | Kinazolinderivater, anvendelse derav og farmasøytisk blanding |
NO2006004C NO2006004I2 (no) | 1995-03-30 | 2006-03-06 | Erlotinib hydroklorid og farmasøytisk akseptable salter derav |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO2006004C NO2006004I2 (no) | 1995-03-30 | 2006-03-06 | Erlotinib hydroklorid og farmasøytisk akseptable salter derav |
Country Status (44)
Families Citing this family (516)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6811779B2 (en) | 1994-02-10 | 2004-11-02 | Imclone Systems Incorporated | Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy |
TW321649B (fr) * | 1994-11-12 | 1997-12-01 | Zeneca Ltd | |
GB9424233D0 (en) * | 1994-11-30 | 1995-01-18 | Zeneca Ltd | Quinazoline derivatives |
GB9508538D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
GB9508535D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivative |
AU5343096A (en) * | 1995-04-27 | 1996-11-18 | Zeneca Limited | Quinazoline derivatives |
GB9508537D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
GB9508565D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
GB9624482D0 (en) * | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
IL125686A (en) | 1996-02-13 | 2002-11-10 | Zeneca Ltd | Quinazoline derivatives, processes for their preparation, pharmaceutical preparations containing them and their use in the manufacture of a drug with an anti-angiogenic effect and / or an effect of reducing vascular permeability |
GB9603095D0 (en) * | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
GB9603097D0 (en) * | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline compounds |
WO1997032856A1 (fr) | 1996-03-05 | 1997-09-12 | Zeneca Limited | Derives de 4-anilinoquinazoline |
DK0892789T4 (da) | 1996-04-12 | 2010-04-06 | Warner Lambert Co | Irreversible inhibitorer af tyrosin kinaser |
GB9607729D0 (en) * | 1996-04-13 | 1996-06-19 | Zeneca Ltd | Quinazoline derivatives |
BR9709959A (pt) * | 1996-06-24 | 2000-05-09 | Pfizer | Derivados tricìclicos de fenilamino substituìdo para o tratamento de doenças hiperproliferativas |
GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
US6225318B1 (en) | 1996-10-17 | 2001-05-01 | Pfizer Inc | 4-aminoquinazolone derivatives |
EP0837063A1 (fr) * | 1996-10-17 | 1998-04-22 | Pfizer Inc. | Dérivés de 4-aminoquinazoline |
US6002008A (en) * | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
DE19743435A1 (de) | 1997-10-01 | 1999-04-08 | Merck Patent Gmbh | Benzamidinderivate |
US6706721B1 (en) | 1998-04-29 | 2004-03-16 | Osi Pharmaceuticals, Inc. | N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate |
CZ298230B6 (cs) * | 1998-04-29 | 2007-08-01 | Osi Pharmaceuticals, Inc. | Anhydrát a monohydrát N-(3-ethinylfenyl)-6,7-bis(2-methoxyethoxy)-4-chinazolinamin mesylátu |
US6384223B1 (en) | 1998-07-30 | 2002-05-07 | American Home Products Corporation | Substituted quinazoline derivatives |
SI1119349T1 (sl) | 1998-08-18 | 2008-12-31 | Univ California | Antagonisti receptorja epidermalnega rastnega faktorja za zdravljenje hipersekrecije sluzi v pljučah |
JP3270834B2 (ja) | 1999-01-27 | 2002-04-02 | ファイザー・プロダクツ・インク | 抗がん剤として有用なヘテロ芳香族二環式誘導体 |
UA71945C2 (en) | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
YU13200A (sh) * | 1999-03-31 | 2002-10-18 | Pfizer Products Inc. | Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja |
SK287010B6 (sk) | 1999-06-21 | 2009-09-07 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Bicyklické heterocyklické zlúčeniny, spôsob ich prípravy, farmaceutický prostriedok s ich obsahom a ich použitie |
ES2295035T3 (es) | 1999-07-09 | 2008-04-16 | Glaxo Group Limited | Anilinoquinazolinas como inhibidores de proteina tirosina quinasa. |
US6933299B1 (en) | 1999-07-09 | 2005-08-23 | Smithkline Beecham Corporation | Anilinoquinazolines as protein tyrosine kinase inhibitors |
GB9922173D0 (en) * | 1999-09-21 | 1999-11-17 | Zeneca Ltd | Chemical compounds |
EP1218356A1 (fr) * | 1999-09-21 | 2002-07-03 | AstraZeneca AB | Composes de quinazoline et compositions pharmaceutiques comprenant lesdits composes |
GB9925958D0 (en) * | 1999-11-02 | 1999-12-29 | Bundred Nigel J | Therapeutic use |
IL149034A0 (en) | 1999-11-05 | 2002-11-10 | Astrazeneca Ab | Quinazoline derivatives as vegf inhibitors |
US7087613B2 (en) | 1999-11-11 | 2006-08-08 | Osi Pharmaceuticals, Inc. | Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride |
UA74803C2 (uk) * | 1999-11-11 | 2006-02-15 | Осі Фармасьютікалз, Інк. | Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування |
KR100858069B1 (ko) | 2000-04-07 | 2008-09-22 | 아스트라제네카 아베 | 퀴나졸린 화합물류 |
UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
EP1170011A1 (fr) * | 2000-07-06 | 2002-01-09 | Boehringer Ingelheim International GmbH | Nouvelle utilisation des inhibiteurs de facteur de croissance épidermique |
PL202812B1 (pl) | 2000-08-21 | 2009-07-31 | Astrazeneca Ab | Pochodna chinazoliny, jej kompozycja famaceutyczna oraz jej zastosowanie |
HU230302B1 (hu) | 2000-10-20 | 2015-12-28 | Eisai R&D Management Co., Ltd. | Nitrogéntartalmú aromás származékok és ezeket tartalmazó gyógyászati készítmények |
US7776315B2 (en) | 2000-10-31 | 2010-08-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions based on anticholinergics and additional active ingredients |
JP4564713B2 (ja) | 2000-11-01 | 2010-10-20 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | 窒素性複素環式化合物、ならびに窒素性複素環式化合物およびその中間体を作製するための方法 |
US7019012B2 (en) | 2000-12-20 | 2006-03-28 | Boehringer Ingelheim International Pharma Gmbh & Co. Kg | Quinazoline derivatives and pharmaceutical compositions containing them |
PT2762140T (pt) | 2001-02-19 | 2017-07-04 | Novartis Ag | Resumo |
JP2002293773A (ja) * | 2001-03-30 | 2002-10-09 | Sumika Fine Chemicals Co Ltd | キナゾリン誘導体の製造方法 |
WO2003000194A2 (fr) | 2001-06-21 | 2003-01-03 | Pfizer Inc. | Derives bicycliques de pyridine et de pyrimidine utiles en tant qu'agents anticancereux |
EP1408980A4 (fr) | 2001-06-21 | 2004-10-20 | Ariad Pharma Inc | Nouvelles quinazolines et leur utilisation |
EP1483268A2 (fr) | 2002-03-01 | 2004-12-08 | Pfizer Inc. | Derives indolyl-uree de thienopyridines utilises comme agents antiangiogeniques, et leurs methodes d'utilisation |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
US7078409B2 (en) | 2002-03-28 | 2006-07-18 | Beta Pharma, Inc. | Fused quinazoline derivatives useful as tyrosine kinase inhibitors |
US6924285B2 (en) | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
DE10221018A1 (de) | 2002-05-11 | 2003-11-27 | Boehringer Ingelheim Pharma | Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie |
DE60324416D1 (de) | 2002-05-16 | 2008-12-11 | Novartis Ag | Verwendung von edg rezeptor bindenden wirkstoffen für die krebstherapie |
UA77303C2 (en) | 2002-06-14 | 2006-11-15 | Pfizer | Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use |
ES2376165T3 (es) | 2002-07-15 | 2012-03-09 | F. Hoffmann-La Roche Ag | Tratamiento del c�?ncer con el anticuerpo dirigido contra erbb2 rhumab 2c4. |
EP2345671B8 (fr) | 2002-09-27 | 2023-01-11 | Xencor, Inc. | Variantes FC optimisées et leurs procédés de génération |
CA2506503A1 (fr) | 2002-11-20 | 2004-06-03 | Array Biopharma, Inc. | Cyanoguanidines et cyanoamidines utilisees comme inhibiteurs de erbb2 et egfr |
US7488823B2 (en) | 2003-11-10 | 2009-02-10 | Array Biopharma, Inc. | Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors |
US20060167026A1 (en) * | 2003-01-06 | 2006-07-27 | Hiroyuki Nawa | Antipsychotic molecular-targeting epithelial growth factor receptor |
GB0302882D0 (en) * | 2003-02-07 | 2003-03-12 | Univ Cardiff | Improvements in or relating to agents for the treatment of cardiovascular dysfunction and weight loss |
US7148231B2 (en) * | 2003-02-17 | 2006-12-12 | Hoffmann-La Roche Inc. | [6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)amine hydrochloride polymorph |
US7223749B2 (en) | 2003-02-20 | 2007-05-29 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
PA8595001A1 (es) | 2003-03-04 | 2004-09-28 | Pfizer Prod Inc | Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf) |
US7994159B2 (en) | 2003-03-10 | 2011-08-09 | Eisai R&D Management Co., Ltd. | c-Kit kinase inhibitor |
GB0309850D0 (en) | 2003-04-30 | 2003-06-04 | Astrazeneca Ab | Quinazoline derivatives |
MY150088A (en) | 2003-05-19 | 2013-11-29 | Irm Llc | Immunosuppressant compounds and compositions |
US7417065B2 (en) | 2003-05-19 | 2008-08-26 | Irm Llc | Immunosuppressant compounds and compositions |
CA2527680A1 (fr) | 2003-05-30 | 2005-06-02 | Astrazeneca Uk Limited | Marqueurs de reactivite d'un inhibiteur de la tyrosine kinase du recepteur erbb |
EP1638600A4 (fr) | 2003-06-09 | 2008-06-11 | Samuel Waksal | Procedes d'inhibition de tyrosine-kinases receptrices au moyen d'un antagoniste extracellulaire et d'un antagoniste intracellulaire |
DE602004009097T2 (de) | 2003-06-10 | 2008-06-19 | F. Hoffmann-La Roche Ag | 1.3.4-triaza-phenalen- und 1,3,4,6-tetraazaphenalen-derivate |
US8309562B2 (en) | 2003-07-03 | 2012-11-13 | Myrexis, Inc. | Compounds and therapeutical use thereof |
GB0317665D0 (en) | 2003-07-29 | 2003-09-03 | Astrazeneca Ab | Qinazoline derivatives |
DE602004017479D1 (de) | 2003-08-29 | 2008-12-11 | Pfizer | Als neue antiangiogene mittel geeignete thienopyridinphenylacetamide und derivate davon |
SI1667991T1 (sl) | 2003-09-16 | 2008-10-31 | Astrazeneca Ab | Kinazolinski derivati kot inhibitorji tirozin kinaze |
GB0322409D0 (en) | 2003-09-25 | 2003-10-29 | Astrazeneca Ab | Quinazoline derivatives |
US9714282B2 (en) | 2003-09-26 | 2017-07-25 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
DE10349113A1 (de) | 2003-10-17 | 2005-05-12 | Boehringer Ingelheim Pharma | Verfahren zur Herstellung von Aminocrotonylverbindungen |
KR101520209B1 (ko) | 2003-11-06 | 2015-05-13 | 시애틀 지네틱스, 인크. | 리간드에 접합될 수 있는 모노메틸발린 화합물 |
CN101337930B (zh) | 2003-11-11 | 2010-09-08 | 卫材R&D管理有限公司 | 脲衍生物的制备方法 |
GB0326459D0 (en) | 2003-11-13 | 2003-12-17 | Astrazeneca Ab | Quinazoline derivatives |
AU2004309166B2 (en) | 2003-12-23 | 2008-02-21 | Pfizer Inc. | Novel quinoline derivatives |
ES2315834T3 (es) | 2004-02-03 | 2009-04-01 | Astrazeneca Ab | Derivados de quinazolina. |
ES2554330T3 (es) | 2004-02-19 | 2015-12-18 | Rexahn Pharmaceuticals, Inc. | Derivados de quinazolina y uso terapéutico de los mismos |
DK1735348T3 (da) | 2004-03-19 | 2012-07-16 | Imclone Llc | Humant anti-epidermalt vækstfaktorreceptorantistof |
ES2741546T3 (es) | 2004-03-31 | 2020-02-11 | Massachusetts Gen Hospital | Método para determinar la respuesta del cáncer a tratamientos dirigidos al receptor del factor de crecimiento epidérmico |
EP2253614B1 (fr) | 2004-04-07 | 2012-09-19 | Novartis AG | Inhibiteurs de IAP |
CA2565721C (fr) | 2004-05-06 | 2015-10-06 | Bioresponse, L.L.C. | Preparations de diindolymethane destinee de traitement de leiomyomes |
BRPI0510883B8 (pt) | 2004-06-01 | 2021-05-25 | Genentech Inc | composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação |
JP2008504292A (ja) | 2004-06-24 | 2008-02-14 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド | 免疫増強用の化合物 |
SI2471813T1 (sl) | 2004-07-15 | 2015-03-31 | Xencor, Inc. | Optimirane Fc variante |
US20060035893A1 (en) | 2004-08-07 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders |
ATE428421T1 (de) | 2004-09-17 | 2009-05-15 | Eisai R&D Man Co Ltd | Medizinische zusammensetzung mit verbesserter stabilität und reduzierten gelierungseigenschaften |
ES2579805T3 (es) | 2004-09-23 | 2016-08-16 | Genentech, Inc. | Anticuerpos y conjugados modificados por ingeniería genética con cisteína |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
EP1817340B1 (fr) | 2004-11-12 | 2012-05-16 | Xencor, Inc. | Variants fc presentant une liaison modifiee au fcrn |
WO2006064196A1 (fr) | 2004-12-14 | 2006-06-22 | Astrazeneca Ab | Composes de pyrazolopyrimidine en tant qu’agents antitumoraux |
PE20060777A1 (es) | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas |
ATE497762T1 (de) | 2004-12-30 | 2011-02-15 | Bioresponse Llc | Verwendung von diindolylmethan-verwandten indolen zur behandlung und prävention von erkrankungen im zusammenhang mit dem respiratory syncytial virus |
US8258145B2 (en) | 2005-01-03 | 2012-09-04 | Myrexis, Inc. | Method of treating brain cancer |
CA2592900A1 (fr) | 2005-01-03 | 2006-07-13 | Myriad Genetics Inc. | Composes et utilisation therapeutique associee |
US7625911B2 (en) | 2005-01-12 | 2009-12-01 | Mai De Ltd. | Amorphous form of erlotinib hydrochloride and its solid amorphous dispersion |
US20080161251A1 (en) | 2005-01-21 | 2008-07-03 | Astex Therapeutics Limited | Pharmaceutical Compounds |
KR20130089280A (ko) | 2005-01-21 | 2013-08-09 | 제넨테크, 인크. | Her 항체의 고정 용량 투여법 |
GB0501999D0 (en) * | 2005-02-01 | 2005-03-09 | Sentinel Oncology Ltd | Pharmaceutical compounds |
MY152164A (en) | 2005-02-23 | 2014-08-15 | Genentech Inc | Extending time to disease progression or survival in cancer patients |
BRPI0606905B1 (pt) * | 2005-02-23 | 2021-06-01 | Shionogi & Co., Ltd. | Derivados de quinazolina tendo atividade inibitória de tirosina cinase e composição farmacêutica que os compreende |
EP1856095B1 (fr) | 2005-02-26 | 2011-08-24 | AstraZeneca AB | Dérivés de quinazoline servant d'inhibiteurs de tyrosine kinase |
ME01222B (me) | 2005-02-28 | 2013-06-20 | Eisai R&D Man Co Ltd | Nova kombinovana upotreba jedinjenja sulfonamida u liječenju kancera |
BRPI0607537A2 (pt) * | 2005-04-12 | 2009-09-15 | Elan Pharma Int Ltd | formulações de derivado de quinazolina nanoparticulado |
CN1854130B (zh) * | 2005-04-15 | 2011-04-20 | 中国医学科学院药物研究所 | 喹唑啉衍生物、及其制法和药物组合物与用途 |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
CA2612449A1 (fr) | 2005-06-17 | 2006-12-28 | Imclone Systems Incorporated | Antagonistes de recepteur pour le traitement de cancer osseux metastatique |
WO2007015578A1 (fr) | 2005-08-02 | 2007-02-08 | Eisai R & D Management Co., Ltd. | Procédé d’analyse de l’effet d’un inhibiteur de vascularisation |
CA2620195A1 (fr) | 2005-08-24 | 2007-03-01 | Bristol-Myers Squibb Company | Marqueurs biologiques et procedes permettant de determiner la receptivite aux modulateurs du recepteur du facteur de croissance epidermique (egfr) |
JP2009508918A (ja) | 2005-09-20 | 2009-03-05 | アストラゼネカ アクチボラグ | 癌治療のためのerbB受容体チロシンキナーゼ阻害剤としての4−(1H−インダゾール−5−イル]アミノ)キナゾリン化合物 |
AU2006299429B2 (en) | 2005-10-03 | 2012-02-23 | Xencor, Inc. | Fc variants with optimized Fc receptor binding properties |
CA2627598C (fr) | 2005-11-07 | 2013-06-25 | Eisai R & D Management Co., Ltd. | Utilisation d'une combinaison de substance anti-angiogenique et d'inhibiteur de kinase c-kit |
WO2007054550A1 (fr) | 2005-11-11 | 2007-05-18 | Boehringer Ingelheim International Gmbh | Derives de quinazoline pour le traitement des affections cancereuses |
CA2933875C (fr) | 2005-11-21 | 2018-06-26 | Novartis Ag | 40-o-(2-hydroxyethyl)-rapamycine destinee a une utilisation comme seule substance medicamenteuse dans le traitement de tumeurs carcinoides provenant de l'intestin anterieur, l'anse vitelline ou l'intestin posterieur |
WO2007060691A2 (fr) * | 2005-11-23 | 2007-05-31 | Natco Pharma Limited | Nouveau procede pour la preparation d'erlotinib |
CN101003514A (zh) | 2006-01-20 | 2007-07-25 | 上海艾力斯医药科技有限公司 | 喹唑啉衍生物、其制备方法及用途 |
JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
CN101484587B (zh) | 2006-02-03 | 2014-02-12 | 英克隆有限责任公司 | Igf-ir拮抗剂作为辅药用于***癌的治疗 |
GB0605120D0 (en) | 2006-03-14 | 2006-04-26 | Novartis Ag | Organic Compounds |
EP2314297A1 (fr) | 2006-04-05 | 2011-04-27 | Novartis AG | Combinaisons d'inhibiteurs de bcr-abl/c-kit/pdgf-r tk pour traiter le cancer |
EP2591775A1 (fr) | 2006-04-05 | 2013-05-15 | Novartis AG | Combinaisons comprenant des inhibiteurs de mTOR pour le traitement du cancer |
AR060358A1 (es) | 2006-04-06 | 2008-06-11 | Novartis Vaccines & Diagnostic | Quinazolinas para la inhibicion de pdk 1 |
CN101472915A (zh) | 2006-04-19 | 2009-07-01 | 诺瓦提斯公司 | 吲唑化合物和抑制cdc7的方法 |
AU2007247112B2 (en) | 2006-05-09 | 2010-08-26 | Novartis Ag | Combination comprising an iron chelator and an anti-neoplastic agent and use thereof |
RU2448708C3 (ru) | 2006-05-18 | 2017-09-28 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Противоопухолевое средство против рака щитовидной железы |
WO2007138612A2 (fr) * | 2006-05-25 | 2007-12-06 | Vittal Mallya Scientific Research Foundation | Procédé de synthèse de [6,7-bis-(2-méthoxyéthoxy)-quinazolin-4- yl]-(3-éthynylphényl)amine hydrochlorure |
WO2007138613A2 (fr) * | 2006-05-25 | 2007-12-06 | Vittal Mallya Scientific Research Foundation | Procédé de synthèse de [6,7-bis-(2-méthoxyéthoxy)-quinazolin-4- yl]-(3-éthynylphényl)amine hydrochlorure |
WO2008012105A1 (fr) * | 2006-07-28 | 2008-01-31 | Synthon B.V. | Forme cristalline d'erlobtinib |
AU2007285976B2 (en) | 2006-08-14 | 2011-08-18 | Xencor, Inc | Optimized antibodies that target CD19 |
KR101472600B1 (ko) | 2006-08-28 | 2014-12-15 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 미분화형 위암에 대한 항종양제 |
CA2662236A1 (fr) | 2006-09-12 | 2008-03-20 | Genentech, Inc. | Procedes et compositions pour le diagnostic et le traitement du cancer |
BRPI0717586A2 (pt) | 2006-09-18 | 2013-10-29 | Boehringer Ingelheim Int | Método para tratar câncer apresentando mutações do egfr |
ATE502943T1 (de) | 2006-09-29 | 2011-04-15 | Novartis Ag | Pyrazolopyrimidine als pi3k-lipidkinasehemmer |
KR101129868B1 (ko) | 2006-10-04 | 2012-04-12 | 화이자 프로덕츠 인코포레이티드 | 칼슘 수용체 길항제로서의 피리도[4,3-d]피리미딘-4(3H)-온 유도체 |
EP2073803B1 (fr) | 2006-10-12 | 2018-09-19 | Astex Therapeutics Limited | Combinaisons pharmaceutiques |
WO2008044045A1 (fr) | 2006-10-12 | 2008-04-17 | Astex Therapeutics Limited | Combinaisons pharmaceutiques |
US8586621B2 (en) | 2006-10-27 | 2013-11-19 | Michael A. Zeligs | Anti-parasitic methods and compositions utilizing diindolylmethane-related indoles |
US8372856B2 (en) | 2006-10-27 | 2013-02-12 | Synthon Bv | Hydrates of erlotinib hydrochloride |
EP1921070A1 (fr) | 2006-11-10 | 2008-05-14 | Boehringer Ingelheim Pharma GmbH & Co. KG | heterocycles bicycliques, medicaments á base de ces composes, leur usage et procédé pour leur preparation |
US8343950B2 (en) * | 2006-12-15 | 2013-01-01 | Concert Pharmaceuticals, Inc. | Quinazoline derivatives and methods of treatment |
JPWO2008088088A1 (ja) | 2007-01-19 | 2010-05-13 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 膵癌治療用組成物 |
WO2008093855A1 (fr) | 2007-01-29 | 2008-08-07 | Eisai R & D Management Co., Ltd. | Composition destinée au traitement d'un cancer de l'estomac de type indifférencié |
EP2118075A1 (fr) | 2007-02-06 | 2009-11-18 | Boehringer Ingelheim International GmbH | Hétérocycles bicycliques, agents pharmaceutiques contenant ces composés, leur utilisation et leur procédé de préparation |
CN101245050A (zh) | 2007-02-14 | 2008-08-20 | 上海艾力斯医药科技有限公司 | 4-苯胺喹唑啉衍生物的盐 |
MX2009008584A (es) | 2007-02-15 | 2009-08-18 | Novartis Ag | Combinacion de lbh589 con otros agentes terapeuticos para el tratamiento de cancer. |
EP2170844B1 (fr) | 2007-02-21 | 2016-05-04 | Natco Pharma Limited | Nouveaux polymorphes destinés de chlorhydrate d'erlotinibe et procédé de fabrication |
BRPI0808418A2 (pt) | 2007-03-02 | 2014-07-22 | Genentech Inc | Predição de resposta a um inibidor de her |
EP2139868B1 (fr) | 2007-04-04 | 2015-07-29 | Cipla Limited | Procédé de préparation de l'erlotinib et de ses sels pharmaceutiquement acceptables |
WO2008150494A1 (fr) | 2007-05-30 | 2008-12-11 | Xencor, Inc. | Procédés et compositions permettant l'inhibition de cellules d'expression du cd32b |
DK2171090T3 (da) | 2007-06-08 | 2013-06-10 | Genentech Inc | Genekspressionsmarkører for tumorresistens over for HER2-inhibitorbehandling |
WO2009012283A1 (fr) | 2007-07-17 | 2009-01-22 | Plexxikon Inc. | Composés et procédés pour la modulation des kinases et leurs indications |
WO2009030224A2 (fr) * | 2007-09-07 | 2009-03-12 | Schebo Biotech Ag | Nouveaux produits pharmaceutiques, procédés pour les produire et leur utilisation en thérapie médicale |
MY150054A (en) | 2007-10-29 | 2013-11-29 | Natco Pharma Ltd | Novel 4-(tetrazol-5-yl)-quinazoline derivatives as anti cancer agents |
WO2009060945A1 (fr) | 2007-11-09 | 2009-05-14 | Eisai R & D Management Co., Ltd. | Combinaison d'une substance antiangiogénique et d'un complexe de platine antitumoral |
UY31478A1 (es) | 2007-11-21 | 2009-07-17 | Inhibicion del receptor para la proteina estimulante del macrofago (ron) y métodos para el tratamiento de lo mismo | |
PE20091523A1 (es) | 2007-12-20 | 2009-10-29 | Novartis Ag | Derivados de tiazol como inhibidores de la enzima fosfatidilinositol 3-cinasa (pi3k) |
KR101616758B1 (ko) | 2007-12-26 | 2016-04-29 | 젠코어 인코포레이티드 | FcRn에 대한 변경된 결합성을 갖는 Fc 변이체 |
ES2593321T3 (es) | 2008-01-18 | 2016-12-07 | Natco Pharma Limited | Derivados de 6,7-dialcoxi-quinazolina útiles para el tratamiento de trastornos relacionados con el cáncer |
TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至her2結構域ii之抗體及其酸性變異體的組合物 |
EA019709B1 (ru) | 2008-02-07 | 2014-05-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Спирогетероциклы и их применение в качестве лекарственных средств |
US8222424B2 (en) | 2008-03-24 | 2012-07-17 | Novartis Ag | Arylsulfonamide-based matrix metalloprotease inhibitors |
CN101544609A (zh) | 2008-03-25 | 2009-09-30 | 上海艾力斯医药科技有限公司 | 4-苯胺喹唑啉衍生物的结晶形式 |
EP2628726A1 (fr) | 2008-03-26 | 2013-08-21 | Novartis AG | Inhibiteurs à hydroxamate de désacétylases B |
CN102083801A (zh) * | 2008-03-28 | 2011-06-01 | 康瑟特制药公司 | 喹唑啉衍生物和治疗方法 |
EA019183B1 (ru) | 2008-05-13 | 2014-01-30 | Астразенека Аб | Фумаратная соль 4-(3-хлор-2-фторанилино)-7-метокси-6-{[1-(n-метилкарбамоилметил)пиперидин-4-ил]окси}хиназолина |
EP2288727B1 (fr) | 2008-05-14 | 2013-07-10 | Genomic Health, Inc. | Prédicteurs de réponse de patient à un traitement avec des inhibiteurs des récepteurs de egf |
CN101584696A (zh) | 2008-05-21 | 2009-11-25 | 上海艾力斯医药科技有限公司 | 包含喹唑啉衍生物的组合物及制备方法、用途 |
DE102008031039A1 (de) | 2008-06-30 | 2009-12-31 | Dömling, Alexander, Priv.-Doz. Dr. | Tarceva zur Anwendung in der Organtransplantation. |
WO2010015522A1 (fr) | 2008-08-08 | 2010-02-11 | Boehringer Ingelheim International Gmbh | Hétérocycles à substitution cyclohexyloxy, médicaments contenant ces composés, leur utilisation et procédés pour les préparer |
WO2010043050A1 (fr) | 2008-10-16 | 2010-04-22 | Celator Pharmaceuticals Corporation | Combinaisons d'une camptothécine de liposome soluble dans l'eau avec du cetuximab ou du bevacizumab |
EP2349235A1 (fr) | 2008-11-07 | 2011-08-03 | Triact Therapeutics, Inc. | Utilisation de dérivés de butane catécholique dans la thérapie du cancer |
EA018624B1 (ru) | 2008-11-11 | 2013-09-30 | Эли Лилли Энд Компани | Комбинированная терапия ингибитором киназы p70 s6 и ингибитором egfr |
US20120115840A1 (en) | 2008-12-18 | 2012-05-10 | Lech Ciszewski | Hemifumarate salt of 1-[4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl]-azetidine-3-carboxylic acid |
KR20110112352A (ko) | 2008-12-18 | 2011-10-12 | 노파르티스 아게 | 1-(4-{l-[(e)-4-시클로헥실-3-트리플루오로메틸-벤질옥시이미노]-에틸}-2-에틸-벤질)-아제티딘-3-카르복실산의 신규한 다형체 형태 |
EP2379499B1 (fr) | 2008-12-18 | 2014-04-09 | Novartis AG | Sel chlorhydrate d'acide 1-[4-[1-((e)-4-cyclohexyl-3-trifluorométhyl-benzyloxyimino)-éthyl]-2-éthyl-benzyl]-azétidine-3-carboxylique |
WO2010083617A1 (fr) | 2009-01-21 | 2010-07-29 | Oncalis Ag | Pyrazolopyrimidines en tant qu'inhibiteurs de protéines kinases |
JP2012516345A (ja) | 2009-01-29 | 2012-07-19 | ノバルティス アーゲー | 星細胞腫治療用置換ベンゾイミダゾール |
EP2213281A1 (fr) | 2009-02-02 | 2010-08-04 | Ratiopharm GmbH | Composition pharmaceutique comportant du N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride |
WO2010099139A2 (fr) | 2009-02-25 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Thérapie anti-cancer combinée |
EP2400990A2 (fr) | 2009-02-26 | 2012-01-04 | OSI Pharmaceuticals, LLC | Procédés in situ pour surveiller l'état emt de cellules tumorales in vivo |
EP2401614A1 (fr) | 2009-02-27 | 2012-01-04 | OSI Pharmaceuticals, LLC | Méthodes d'identification d'agents qui inhibent les cellules cancéreuses mésenchymateuses ou leur formation |
WO2010099364A2 (fr) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Méthodes d'identification d'agents qui inhibent les cellules cancéreuses mésenchymateuses ou leur formation |
WO2010099138A2 (fr) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Procédés pour l'identification d'agents qui inhibent les cellules tumorales de type mésenchymateuses ou leur formation |
JP2012520893A (ja) | 2009-03-18 | 2012-09-10 | オーエスアイ・ファーマシューティカルズ,エルエルシー | Egfr阻害薬及びigf−1r阻害剤の投与を含む組み合わせ癌治療 |
US8440823B2 (en) * | 2009-03-26 | 2013-05-14 | Ranbaxy Laboratories Limited | Process for the preparation of erlotinib or its pharmaceutically acceptable salts thereof |
UA105794C2 (uk) | 2009-06-26 | 2014-06-25 | Новартіс Аг | 1,3-ДИЗАМІЩЕНІ ПОХІДНІ ІМІДАЗОЛІДИН-2-ОНУ ЯК ІНГІБІТОРИ Cyp17 |
US8293753B2 (en) | 2009-07-02 | 2012-10-23 | Novartis Ag | Substituted 2-carboxamide cycloamino ureas |
WO2011003853A2 (fr) | 2009-07-06 | 2011-01-13 | Boehringer Ingelheim International Gmbh | Procédé de séchage du bibw2992, de ses sels et des préparations pharmaceutiques solides contenant ce principe actif |
US9050341B2 (en) * | 2009-07-14 | 2015-06-09 | Natco Pharma Limited | Methods of treating drug resistant and other tumors by administering 6,7-dialkoxy quinazoline derivatives |
US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
US8389526B2 (en) | 2009-08-07 | 2013-03-05 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives |
AU2010283806A1 (en) | 2009-08-12 | 2012-03-01 | Novartis Ag | Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation |
ES2709108T3 (es) | 2009-08-17 | 2019-04-15 | Intellikine Llc | Compuestos heterocíclicos y usos de los mismos |
AU2010284972A1 (en) | 2009-08-20 | 2012-03-08 | Novartis Ag | Heterocyclic oxime compounds |
EA201200321A1 (ru) | 2009-08-26 | 2012-09-28 | Новартис Аг | Тетразамещенные гетероарильные соединения и их применение в качестве модуляторов mdm2 и/или mdm4 |
US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
WO2011053779A2 (fr) | 2009-10-30 | 2011-05-05 | Bristol-Myers Squibb Company | Méthodes pour traiter un cancer chez des patients présentant une résistance à l'inhibiteur d'igf-1r |
MX2012005293A (es) | 2009-11-04 | 2012-06-19 | Novartis Ag | Derivados de sulfonamida heterociclicos utiles como inhibidores de mek. |
US20120316187A1 (en) | 2009-11-13 | 2012-12-13 | Pangaea Biotech, S.L. | Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer |
US10584181B2 (en) | 2009-12-04 | 2020-03-10 | Genentech, Inc. | Methods of making and using multispecific antibody panels and antibody analog panels |
JP5456908B2 (ja) | 2009-12-08 | 2014-04-02 | ノバルティス アーゲー | ヘテロ環式スルホンアミド誘導体 |
CU24130B1 (es) | 2009-12-22 | 2015-09-29 | Novartis Ag | Isoquinolinonas y quinazolinonas sustituidas |
US8440693B2 (en) | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
EP2348020A1 (fr) | 2009-12-23 | 2011-07-27 | Esteve Química, S.A. | Procédé de préparation d'erlotinib |
CN102712640A (zh) | 2010-01-12 | 2012-10-03 | 弗·哈夫曼-拉罗切有限公司 | 三环杂环化合物、其组合物和应用方法 |
AU2011222867B2 (en) | 2010-03-04 | 2014-03-06 | Annika Algars | Method for selecting patients for treatment with an EGFR inhibitor |
KR20130001272A (ko) | 2010-03-17 | 2013-01-03 | 에프. 호프만-라 로슈 아게 | 이미다조피리딘 및 푸린 화합물, 조성물 및 사용 방법 |
WO2011120134A1 (fr) | 2010-03-29 | 2011-10-06 | Zymeworks, Inc. | Anticorps présentant une fonction effectrice améliorée ou supprimée |
EP2558864A1 (fr) | 2010-04-16 | 2013-02-20 | Genentech, Inc. | Foxo3a utilisée comme biomarqueur prédictif pour l'efficacité d'un inhibiteur de la voie des kinases p13k/akt |
DE202010006543U1 (de) | 2010-05-07 | 2010-09-09 | Ratiopharm Gmbh | Erlotinibresinat |
WO2011146568A1 (fr) | 2010-05-19 | 2011-11-24 | Genentech, Inc. | Prédiction de réponses à un inhibiteur de her |
BR112012028964A2 (pt) | 2010-05-21 | 2016-07-26 | Shanghai Inst Pharm Industry | quinazolinas policíclicas, método de preparação das mesmas e seus usos |
WO2011147102A1 (fr) * | 2010-05-28 | 2011-12-01 | 翔真生物科技股份有限公司 | Procédé de synthèse d'une 4-aniline-quinazoline substituée aux positions 6 et 7 |
BR112012032462A2 (pt) | 2010-06-25 | 2016-11-08 | Eisai R&D Man Co Ltd | agente antitumoral empregando compostos que, em combinação, têm efeito inibidor de quinase. |
UA112517C2 (uk) | 2010-07-06 | 2016-09-26 | Новартіс Аг | Тетрагідропіридопіримідинові похідні |
US8952022B2 (en) * | 2010-07-23 | 2015-02-10 | Generics [Uk] Limited | Pure erlotinib |
AR082418A1 (es) | 2010-08-02 | 2012-12-05 | Novartis Ag | Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico |
KR20130051507A (ko) | 2010-09-15 | 2013-05-20 | 에프. 호프만-라 로슈 아게 | 아자벤조티아졸 화합물, 조성물 및 사용 방법 |
JP2013537210A (ja) | 2010-09-16 | 2013-09-30 | ノバルティス アーゲー | 17α−ヒドロキシラーゼ/C17,20−リアーゼ阻害剤 |
IT1402029B1 (it) | 2010-10-14 | 2013-08-28 | Italiana Sint Spa | Procedimento per la preparazione di erlotinib |
US9309322B2 (en) | 2010-11-12 | 2016-04-12 | Scott & White Healthcare (Swh) | Antibodies to tumor endothelial marker 8 |
KR20140009259A (ko) | 2010-11-19 | 2014-01-22 | 에프. 호프만-라 로슈 아게 | 피라졸로피리딘 및 tyk2 억제제로서 이의 용도 |
JP5808818B2 (ja) * | 2010-11-25 | 2015-11-10 | ラツィオファーム・ゲーエムベーハー | アファチニブの新規塩及び多形形態 |
DE102010053124A1 (de) | 2010-12-01 | 2012-06-06 | Volkswagen Ag | Kupplung, insbesondere für ein Getriebe eines Kraftfahrzeuges, vorzugsweise Doppelkupplung für ein automatisches oder automatisiertes Doppelkupplungsgetriebe |
BR112013015449A2 (pt) | 2010-12-21 | 2016-09-20 | Novartis Ag | compostos de bi-heteroarila como inibidores de vps23 |
EP2468883A1 (fr) | 2010-12-22 | 2012-06-27 | Pangaea Biotech S.L. | Biomarqueurs moléculaires pour la prédiction de la réponse aux inhibiteurs de la tyrosine kinase dans le cancer du poumon |
WO2012085176A1 (fr) | 2010-12-23 | 2012-06-28 | F. Hoffmann-La Roche Ag | Composés pyrazinones tricycliques, leurs compositions et leurs procédés d'utilisation en tant qu'inhibiteurs de janus kinase |
US9134297B2 (en) | 2011-01-11 | 2015-09-15 | Icahn School Of Medicine At Mount Sinai | Method and compositions for treating cancer and related methods |
UY33883A (es) | 2011-01-31 | 2012-08-31 | Novartis Ag | Novedosos derivados heterocíclicos |
EP2673277A1 (fr) | 2011-02-10 | 2013-12-18 | Novartis AG | Composés de [1, 2, 4]triazolo [4, 3 -b]pyridazine en tant qu'inhibiteurs de la tyrosine kinase c-met |
US9127000B2 (en) | 2011-02-23 | 2015-09-08 | Intellikine, LLC. | Heterocyclic compounds and uses thereof |
EP2492688A1 (fr) | 2011-02-23 | 2012-08-29 | Pangaea Biotech, S.A. | Biomarqueurs moléculaires pour la prédiction de la réponse à un traitement antitumoral dans le cancer du poumon |
KR20210043016A (ko) | 2011-03-04 | 2021-04-20 | 뉴젠 세러퓨틱스 인코포레이티드 | 알킨 치환된 퀴나졸린 화합물 및 그것의 사용 방법 |
JP5832559B2 (ja) | 2011-03-10 | 2015-12-16 | オメロス コーポレーション | exvivoにおける加速された抗体進化による抗FN14モノクローナル抗体の生成 |
WO2012129145A1 (fr) | 2011-03-18 | 2012-09-27 | OSI Pharmaceuticals, LLC | Polythérapie du cancer du poumon non à petites cellules (nsclc) |
CN103402519B (zh) | 2011-04-18 | 2015-11-25 | 卫材R&D管理有限公司 | 肿瘤治疗剂 |
WO2012149014A1 (fr) | 2011-04-25 | 2012-11-01 | OSI Pharmaceuticals, LLC | Utilisation de signatures de gènes de tem dans la découverte de médicaments contre le cancer, diagnostics et traitement du cancer |
GB201106870D0 (en) | 2011-04-26 | 2011-06-01 | Univ Belfast | Marker |
JP6002210B2 (ja) | 2011-04-28 | 2016-10-05 | ノバルティス アーゲー | 17α−ヒドロキシラーゼ/C17,20−リアーゼ阻害剤 |
CN102918029B (zh) | 2011-05-17 | 2015-06-17 | 江苏康缘药业股份有限公司 | 4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途 |
JP6038128B2 (ja) | 2011-06-03 | 2016-12-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー |
CA2838029A1 (fr) | 2011-06-09 | 2012-12-13 | Novartis Ag | Derives de sulfonamide heterocyclique |
WO2012175487A1 (fr) | 2011-06-20 | 2012-12-27 | Novartis Ag | Composés de cyclohexyl-isoquinolinone |
US8859535B2 (en) | 2011-06-20 | 2014-10-14 | Novartis Ag | Hydroxy substituted isoquinolinone derivatives |
CN102267952B (zh) * | 2011-06-21 | 2013-12-11 | 天津市汉康医药生物技术有限公司 | 喹唑啉类化合物、其制备方法和用途 |
KR20140025530A (ko) | 2011-06-27 | 2014-03-04 | 노파르티스 아게 | 테트라히드로-피리도-피리미딘 유도체의 고체 형태 및 염 |
US8575339B2 (en) * | 2011-07-05 | 2013-11-05 | Xueheng Cheng | Derivatives of erlotinib |
WO2013007765A1 (fr) | 2011-07-13 | 2013-01-17 | F. Hoffmann-La Roche Ag | Composés tricycliques fusionnés utilisés en tant qu'inhibiteurs des janus kinases |
WO2013007768A1 (fr) | 2011-07-13 | 2013-01-17 | F. Hoffmann-La Roche Ag | Composés hétérocycliques tricycliques, compositions et procédés d'utilisation de ces composés comme inhibiteurs des jak |
WO2013024011A1 (fr) | 2011-08-12 | 2013-02-21 | F. Hoffmann-La Roche Ag | Composés d'indazole, compositions et procédés d'utilisation |
EP3392274A1 (fr) | 2011-08-12 | 2018-10-24 | Omeros Corporation | Anticorps monoclonaux anti-fzd10 et leurs procédés d'utilisation |
KR20140057356A (ko) | 2011-08-31 | 2014-05-12 | 제넨테크, 인크. | 진단 마커 |
BR112014006223A8 (pt) | 2011-09-15 | 2018-01-09 | Novartis Ag | 3-(quinolin-6-iltio)-[1,2,4-triazol[4,3-a] piradinas 6-substituídas, seus usos, composições farmacêuticas, e combinação |
CA2845409A1 (fr) | 2011-09-20 | 2013-03-28 | Yingjie Lai | Compose imidazopyridine, compositions et procedes d'utilisation |
US20130084287A1 (en) | 2011-09-30 | 2013-04-04 | Genentech, Inc. | Diagnostic markers |
HU230483B1 (hu) | 2011-10-10 | 2016-07-28 | Egis Gyógyszergyár Nyrt. | Erlotinib sók |
WO2013056069A1 (fr) | 2011-10-13 | 2013-04-18 | Bristol-Myers Squibb Company | Procédés de sélection et de traitement du cancer chez des patients au moyen d'inhibiteurs de l'igf-1r/ir |
WO2013061305A1 (fr) | 2011-10-28 | 2013-05-02 | Novartis Ag | Nouveaux dérivés de purine et utilisation de ceux-ci dans le traitement d'une maladie |
EP2785717B1 (fr) | 2011-11-29 | 2016-01-13 | Novartis AG | Composés pyrazolopyrrolidine |
US9408885B2 (en) | 2011-12-01 | 2016-08-09 | Vib Vzw | Combinations of therapeutic agents for treating melanoma |
PE20141598A1 (es) | 2011-12-22 | 2014-11-14 | Novartis Ag | Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina |
WO2013093850A1 (fr) | 2011-12-22 | 2013-06-27 | Novartis Ag | Dérivés quinoline |
MX2014007729A (es) | 2011-12-23 | 2015-01-12 | Novartis Ag | Compuestos para inhibir la interaccion de bcl2 con los componentes de enlace. |
KR20140107578A (ko) | 2011-12-23 | 2014-09-04 | 노파르티스 아게 | Bcl2와 결합 파트너의 상호작용을 억제하기 위한 화합물 |
CN104136429A (zh) | 2011-12-23 | 2014-11-05 | 诺华股份有限公司 | 用于抑制bcl2与结合配偶体相互作用的化合物 |
MX2014007730A (es) | 2011-12-23 | 2015-01-12 | Novartis Ag | Compuestos para inhibir la interaccion de bcl2 con los componentes de enlace. |
WO2013096060A1 (fr) | 2011-12-23 | 2013-06-27 | Novartis Ag | Composés inhibiteurs de l'interaction entre bcl2 et des partenaires de liaison |
US8815926B2 (en) | 2012-01-26 | 2014-08-26 | Novartis Ag | Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases |
EA201400993A1 (ru) | 2012-03-08 | 2015-05-29 | Галозим, Инк. | Антитела против рецептора эпидермального фактора роста, активные в определенных условиях, и способы их применения |
EP2831115A1 (fr) | 2012-03-27 | 2015-02-04 | F. Hoffmann-La Roche AG | Diagnostic et traitements concernant des inhibiteurs de her3 |
CN104245701A (zh) | 2012-04-03 | 2014-12-24 | 诺华有限公司 | 有酪氨酸激酶抑制剂的组合产品和其应用 |
WO2013152252A1 (fr) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Polythérapie antinéoplasique |
US10213432B2 (en) | 2012-05-16 | 2019-02-26 | Novartis Ag | Dosage regimen for a PI-3 kinase inhibitor |
EP2855483B1 (fr) | 2012-05-24 | 2017-10-25 | Novartis AG | Composés pyrrolopyrrolidinones |
JP6427097B2 (ja) | 2012-06-15 | 2018-11-21 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. | 癌を処置するための組成物および該組成物を製造するための方法 |
WO2013190089A1 (fr) | 2012-06-21 | 2013-12-27 | Pangaea Biotech, S.L. | Biomarqueurs moléculaires permettant de prédire l'issue dans le cancer du poumon |
NZ630289A (en) | 2012-09-04 | 2016-08-26 | Shilpa Medicare Ltd | Crystalline erlotinib hydrochloride process |
TW201422625A (zh) | 2012-11-26 | 2014-06-16 | Novartis Ag | 二氫-吡啶并-□衍生物之固體形式 |
CN104755463A (zh) | 2012-12-21 | 2015-07-01 | 卫材R&D管理有限公司 | 非晶态形式的喹啉衍生物及其生产方法 |
WO2014115077A1 (fr) | 2013-01-22 | 2014-07-31 | Novartis Ag | Composés de purinone substitués |
EP2948453B1 (fr) | 2013-01-22 | 2017-08-02 | Novartis AG | Composés pyrazolo[3,4-d]pyrimidinone utilisés en tant qu'inhibiteurs de l'interaction p53/mdm2 |
WO2014118112A1 (fr) | 2013-01-29 | 2014-08-07 | Synthon B.V. | Composition pharmaceutique comprenant du chlorhydrate d'erlotinib |
WO2014128612A1 (fr) | 2013-02-20 | 2014-08-28 | Novartis Ag | Dérivés de quinazolin-4-one |
EP2961412A4 (fr) | 2013-02-26 | 2016-11-09 | Triact Therapeutics Inc | Cancérothérapie |
KR20150130491A (ko) | 2013-03-13 | 2015-11-23 | 제넨테크, 인크. | 피라졸로 화합물 및 그것의 용도 |
EP2968340A4 (fr) | 2013-03-15 | 2016-08-10 | Intellikine Llc | Combinaison d'inhibiteurs de kinase et ses utilisations |
EP2976085A1 (fr) | 2013-03-21 | 2016-01-27 | INSERM - Institut National de la Santé et de la Recherche Médicale | Méthode et composition pharmaceutique pour l'utilisation dans le traitement de maladies hépatiques chroniques associées à une faible expression d'hepcidine |
WO2014155268A2 (fr) | 2013-03-25 | 2014-10-02 | Novartis Ag | Inhibiteurs de kinase tyrosine fgf-r et leur utilisation dans le traitement de maladies associées à un manque ou à une absence d'activité snf5 |
MX368099B (es) | 2013-05-14 | 2019-09-19 | Eisai R&D Man Co Ltd | Biomarcadores para predecir y evaluar el grado de respuesta de sujetos con cancer de endometrio a compuestos de tipo lenvatinib. |
US20150018376A1 (en) | 2013-05-17 | 2015-01-15 | Novartis Ag | Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof |
UY35675A (es) | 2013-07-24 | 2015-02-27 | Novartis Ag | Derivados sustituidos de quinazolin-4-ona |
WO2015022664A1 (fr) | 2013-08-14 | 2015-02-19 | Novartis Ag | Composés et compositions utiles comme inhibiteurs de mek |
WO2015022663A1 (fr) | 2013-08-14 | 2015-02-19 | Novartis Ag | Composés et compositions utiles comme inhibiteurs de mek |
US9227969B2 (en) | 2013-08-14 | 2016-01-05 | Novartis Ag | Compounds and compositions as inhibitors of MEK |
MX2016002794A (es) | 2013-09-05 | 2016-09-13 | Genentech Inc | Compuestos antiproliferativos. |
EP3044593A4 (fr) | 2013-09-09 | 2017-05-17 | Triact Therapeutics, Inc. | Traitement du cancer |
KR20160055253A (ko) | 2013-09-12 | 2016-05-17 | 할로자임, 아이엔씨 | 변형된 항-상피세포 성장인자 수용체 항체 및 이의 사용 방법 |
CA2920059A1 (fr) | 2013-09-22 | 2015-03-26 | Calitor Sciences, Llc | Composes d'aminopyrimidine substituee et procedes d'utilisation |
TW201605857A (zh) | 2013-10-03 | 2016-02-16 | 赫孚孟拉羅股份公司 | Cdk8之醫療性抑制劑及其用途 |
WO2015084804A1 (fr) | 2013-12-03 | 2015-06-11 | Novartis Ag | Combinaison d'un inhibiteur de mdm2 et d'un inhibiteur de braf, et leur utilisation |
JP2016539149A (ja) | 2013-12-06 | 2016-12-15 | ノバルティス アーゲー | アルファ−アイソフォーム選択的ホスファチジルイノシトール3−キナーゼ阻害剤の投薬レジメン |
SG11201604979WA (en) | 2013-12-17 | 2016-07-28 | Genentech Inc | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
MX2016007887A (es) | 2013-12-17 | 2016-10-28 | Genentech Inc | Metodos de tratamiento de canceres positivos a her2 usando antagonistas de union del eje de pd-1 y anticuerpos anti-her2. |
US9242965B2 (en) | 2013-12-31 | 2016-01-26 | Boehringer Ingelheim International Gmbh | Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors |
WO2015145388A2 (fr) | 2014-03-27 | 2015-10-01 | Novartis Ag | Procédés de traitement de cancers colorectaux avec mutations en amont de la voie wnt |
EP3327006B1 (fr) | 2014-03-28 | 2020-05-20 | Calitor Sciences, LLC | Composés d'hétéroaryle substitués et procédés d'utilisation |
PT3126394T (pt) | 2014-03-31 | 2019-12-19 | Hoffmann La Roche | Anticorpos anti-ox40 e métodos de utilização |
MX2016012779A (es) | 2014-03-31 | 2017-04-27 | Genentech Inc | Terapia de combinacion con agentes antiangiogénesis y agonistas de unión a ox40. |
JP2017513931A (ja) | 2014-04-03 | 2017-06-01 | インビクタス オンコロジー ピーヴィティー.リミテッド | 超分子コンビナトリアル治療薬 |
WO2015156674A2 (fr) | 2014-04-10 | 2015-10-15 | Stichting Het Nederlands Kanker Instituut | Méthode de traitement du cancer |
WO2016011658A1 (fr) | 2014-07-25 | 2016-01-28 | Novartis Ag | Polythérapie |
MX2017001461A (es) | 2014-07-31 | 2017-05-11 | Novartis Ag | Terapia de combinacion. |
KR102329681B1 (ko) | 2014-08-28 | 2021-11-23 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 고순도의 퀴놀린 유도체 및 이를 제조하는 방법 |
WO2016036873A1 (fr) | 2014-09-05 | 2016-03-10 | Genentech, Inc. | Composés thérapeutiques et leurs utilisations |
EP3193866A1 (fr) | 2014-09-19 | 2017-07-26 | Genentech, Inc. | Utilisation des inhibiteurs cbp/ep300 et bet pour le traitement du cancer |
JP6783230B2 (ja) | 2014-10-10 | 2020-11-11 | ジェネンテック, インコーポレイテッド | ヒストンデメチラーゼのインヒビターとしてのピロリドンアミド化合物 |
ES2855075T3 (es) | 2014-10-17 | 2021-09-23 | Novartis Ag | Combinación de ceritinib con un inhibidor de EGFR |
CA2908441A1 (fr) | 2014-10-28 | 2016-04-28 | Cerbios-Pharma Sa | Procede de preparation d'erlotinib |
RU2017119231A (ru) | 2014-11-03 | 2018-12-06 | Дженентек, Инк. | Способы и биомаркеры для прогнозирования эффективности и оценки лечения агонистом ох40 |
CA2966523A1 (fr) | 2014-11-03 | 2016-05-12 | Genentech, Inc. | Tests de detection de sous-ensembles immunitaires de cellules t et leurs procedes d'utilisation |
SG11201703376QA (en) | 2014-11-06 | 2017-05-30 | Genentech Inc | Combination therapy comprising ox40 binding agonists and tigit inhibitors |
EP3218376B1 (fr) | 2014-11-10 | 2019-12-25 | Genentech, Inc. | Inhibiteurs de bromodomaine et leurs utilisations |
MA40940A (fr) | 2014-11-10 | 2017-09-19 | Constellation Pharmaceuticals Inc | Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines |
MA40943A (fr) | 2014-11-10 | 2017-09-19 | Constellation Pharmaceuticals Inc | Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines |
US20160166685A1 (en) | 2014-11-17 | 2016-06-16 | Genentech, Inc. | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
EP3224258B1 (fr) | 2014-11-27 | 2019-08-14 | Genentech, Inc. | Composés 4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine utilisés comme inhibiteurs de cbp et/ou de ep300 |
WO2016082879A1 (fr) * | 2014-11-27 | 2016-06-02 | Synthon B.V. | Composition pharmaceutique comportant du chlorhydrate d'erlotinib |
SG11201704707PA (en) | 2014-12-23 | 2017-07-28 | Genentech Inc | Compositions and methods for treating and diagnosing chemotherapy-resistant cancers |
EP3699290A1 (fr) | 2014-12-24 | 2020-08-26 | F. Hoffmann-La Roche AG | Diagnostic thérapeutique et procédés de pronostic de cancer |
EP3240908A2 (fr) | 2014-12-30 | 2017-11-08 | F. Hoffmann-La Roche AG | Procédés et compositions de pronostic et de traitement du cancer |
EP3242872B1 (fr) | 2015-01-09 | 2019-07-03 | Genentech, Inc. | Dérivés du méthanone (pipéridin-3-yl)(naphthalen-2-yl) et composés similaires en tant qu'inhibiteurs de la déméthylase de histone kdm2b pour le traitement de cancer |
CN107406418B (zh) | 2015-01-09 | 2021-10-29 | 基因泰克公司 | 4,5-二氢咪唑衍生物及其作为组蛋白脱甲基酶(kdm2b)抑制剂的用途 |
WO2016112298A1 (fr) | 2015-01-09 | 2016-07-14 | Genentech, Inc. | Dérivés de pyridazinone et leur utilisation dans le traitement du cancer |
JP6709792B2 (ja) | 2015-01-29 | 2020-06-17 | ジェネンテック, インコーポレイテッド | 治療用化合物およびその使用 |
WO2016123387A1 (fr) | 2015-01-30 | 2016-08-04 | Genentech, Inc. | Composés thérapeutiques et leurs utilisations |
MA41598A (fr) | 2015-02-25 | 2018-01-02 | Constellation Pharmaceuticals Inc | Composés thérapeutiques de pyridazine et leurs utilisations |
BR112017017428A2 (pt) | 2015-02-25 | 2018-04-03 | Eisai R&D Management Co., Ltd. | ?método para supressão do amargor de derivado de quinolina? |
CN104725327B (zh) * | 2015-03-03 | 2017-08-25 | 山东大学 | 一种盐酸厄洛替尼的环保制备方法 |
CA2978226A1 (fr) | 2015-03-04 | 2016-09-09 | Merck Sharpe & Dohme Corp. | Association d'un antagoniste de pd-1 et d'un inhibiteur des tyrosines kinases vegfr/fgfr/ret pour traiter le cancer |
EP3280736A1 (fr) | 2015-04-07 | 2018-02-14 | F. Hoffmann-La Roche AG | Complexe de liaison à l'antigène à activité agoniste et ses procédé d'utilisation |
MX2017014381A (es) | 2015-05-12 | 2018-03-02 | Genentech Inc | Metodos terapeuticos y diagnosticos para cancer. |
CN107532217A (zh) | 2015-05-29 | 2018-01-02 | 豪夫迈·罗氏有限公司 | 用于癌症的治疗和诊断方法 |
CN107750164A (zh) | 2015-06-08 | 2018-03-02 | 豪夫迈·罗氏有限公司 | 使用抗ox40抗体和pd‑1轴结合拮抗剂治疗癌症的方法 |
CN107810011A (zh) | 2015-06-08 | 2018-03-16 | 豪夫迈·罗氏有限公司 | 使用抗ox40抗体治疗癌症的方法 |
BR112017027227B1 (pt) | 2015-06-16 | 2023-12-12 | Eisai R&D Management Co., Ltd | Agente anti-câncer |
CN107771076A (zh) | 2015-06-17 | 2018-03-06 | 豪夫迈·罗氏有限公司 | 使用pd‑1轴结合拮抗剂和紫杉烷治疗局部晚期或转移性乳腺癌的方法 |
CN105017162B (zh) * | 2015-06-26 | 2017-10-27 | 陕西师范大学 | 4‑对丙烯基苯氨基喹唑啉衍生物及其在制备抗肿瘤药物中的应用 |
PL3341376T3 (pl) | 2015-08-26 | 2021-08-02 | Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) | Skondensowane związki tricykliczne jako inhibitory kinaz białkowych |
CN108348522A (zh) | 2015-08-28 | 2018-07-31 | 诺华股份有限公司 | 含(a)周期素依赖性激酶4/6(cdk4/6)抑制剂lee011(=ribociclib)和(b)表皮生长因子受体(egfr)抑制剂厄洛替尼的药物组合,用于治疗或预防癌症 |
KR20180050339A (ko) | 2015-09-04 | 2018-05-14 | 오비아이 파머 인코퍼레이티드 | 글리칸 어레이 및 사용 방법 |
WO2017044434A1 (fr) | 2015-09-11 | 2017-03-16 | Sunshine Lake Pharma Co., Ltd. | Composés hétéroaryle substitués et leurs méthodes d'utilisation |
BR112018005862A2 (pt) | 2015-09-25 | 2018-10-16 | Genentech, Inc. | anticorpos, anticorpos isolados, polinucleotídeo, vetor, célula hospedeira, método de produção do anticorpo, imunoconjugado, composição, usos dos anticorpos, métodos para tratar ou retardar a progressão de um câncer e de uma doença e para aumentar, potencializar ou estimular uma resposta ou função imune e kit |
AU2016347881A1 (en) | 2015-11-02 | 2018-05-10 | Novartis Ag | Dosage regimen for a phosphatidylinositol 3-kinase inhibitor |
EP3978500B1 (fr) | 2015-12-16 | 2023-11-22 | Genentech, Inc. | Procédé de préparation de composés tricycliques inhibiteurs de pi3k |
WO2017118675A1 (fr) | 2016-01-08 | 2017-07-13 | F. Hoffmann-La Roche Ag | Procédés permettant de traiter des cancers positifs à cea au moyen d'antagonistes de liaison à l'axe de pd-1 et d'anticorps bispécifiques anti-cea/anti-cd3 |
KR102500659B1 (ko) | 2016-02-29 | 2023-02-16 | 제넨테크, 인크. | 암에 대한 치료 및 진단 방법 |
US10980894B2 (en) | 2016-03-29 | 2021-04-20 | Obi Pharma, Inc. | Antibodies, pharmaceutical compositions and methods |
WO2017172990A1 (fr) | 2016-03-29 | 2017-10-05 | Obi Pharma, Inc. | Anticorps, compositions pharmaceutiques et procédés |
CN109154027A (zh) | 2016-04-15 | 2019-01-04 | 豪夫迈·罗氏有限公司 | 用于监测和治疗癌症的方法 |
JP7503887B2 (ja) | 2016-04-15 | 2024-06-21 | ジェネンテック, インコーポレイテッド | がんを監視及び治療するための方法 |
CN109072311A (zh) | 2016-04-15 | 2018-12-21 | 豪夫迈·罗氏有限公司 | 用于癌症的诊断和治疗方法 |
IL262296B1 (en) | 2016-04-22 | 2024-05-01 | Obi Pharma Inc | Cancer immunotherapy using immune activation or immune modulation by Globo-series antigens |
WO2017194554A1 (fr) | 2016-05-10 | 2017-11-16 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Polythérapies pour le traitement du cancer |
WO2017205536A2 (fr) | 2016-05-24 | 2017-11-30 | Genentech, Inc. | Composés thérapeutiques et leurs utilisations |
CN109476663B (zh) | 2016-05-24 | 2021-11-09 | 基因泰克公司 | 用于治疗癌症的吡唑并吡啶衍生物 |
WO2017214373A1 (fr) | 2016-06-08 | 2017-12-14 | Genentech, Inc. | Procédés diagnostiques et thérapeutiques relatifs au cancer |
JP7148504B2 (ja) | 2016-06-08 | 2022-10-05 | ゼンコー,インコーポレイティド | CD32Bに交差結合した抗CD19抗体を用いたIgG4関連疾患の治療 |
KR20230117482A (ko) | 2016-07-27 | 2023-08-08 | 오비아이 파머 인코퍼레이티드 | 면역원성/치료 글리칸 조성물 및 그의 용도 |
EP3491026A4 (fr) | 2016-07-29 | 2020-07-29 | OBI Pharma, Inc. | Anticorps humains, compositions pharmaceutiques et procédés |
WO2018027204A1 (fr) | 2016-08-05 | 2018-02-08 | Genentech, Inc. | Anticorps multivalents et multiépitopiques ayant une activité agoniste et procédés d'utilisation |
EP3497129A1 (fr) | 2016-08-08 | 2019-06-19 | H. Hoffnabb-La Roche Ag | Méthodes thérapeutiques et de diagnostic du cancer |
WO2018060833A1 (fr) | 2016-09-27 | 2018-04-05 | Novartis Ag | Schéma posologique pour l'alpelisib, un inhibiteur de la phosphatidylinositol 3-kinase spécifique de l'isoforme alpha |
CN110418851A (zh) | 2016-10-06 | 2019-11-05 | 基因泰克公司 | 癌症的治疗和诊断方法 |
WO2018078143A1 (fr) | 2016-10-28 | 2018-05-03 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Moyens et procédés pour déterminer l'efficacité d'inhibiteurs anti-egfr dans une thérapie du cancer colorectal (crc) |
CN110267678A (zh) | 2016-10-29 | 2019-09-20 | 霍夫曼-拉罗奇有限公司 | 抗mic抗体和使用方法 |
AU2017361549B2 (en) | 2016-11-21 | 2023-12-21 | Obi Pharma, Inc. | Conjugated biological molecules, pharmaceutical compositions and methods |
UA124474C2 (uk) | 2016-12-22 | 2021-09-22 | Емджен Інк. | БЕНЗІЗОТІАЗОЛЬНІ, ІЗОТІАЗОЛО[3,4-b]ПІРИДИНОВІ, ХІНАЗОЛІНОВІ, ФТАЛАЗИНОВІ, ПІРИДО[2,3-d]ПІРИДАЗИНОВІ Й ПІРИДО[2,3-d]ПІРИМІДИНОВІ ПОХІДНІ ЯК ІНГІБІТОРИ G12C KRAS ДЛЯ ЛІКУВАННЯ РАКУ ЛЕГЕНІ, РАКУ ПІДШЛУНКОВОЇ ЗАЛОЗИ АБО КОЛОРЕКТАЛЬНОГО РАКУ |
CN110546277B (zh) | 2017-03-01 | 2024-06-11 | 豪夫迈·罗氏有限公司 | 用于癌症的诊断和治疗方法 |
CN106928069B (zh) * | 2017-03-21 | 2019-03-19 | 上海玉函化工有限公司 | 一种4,5-二(2-甲氧基乙氧基)-2-硝基苯甲酸乙酯的制备方法 |
AU2018250875A1 (en) | 2017-04-13 | 2019-10-03 | F. Hoffmann-La Roche Ag | An interleukin-2 immunoconjugate, a CD40 agonist, and optionally a PD-1 axis binding antagonist for use in methods of treating cancer |
JOP20190272A1 (ar) | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
CN107200715B (zh) * | 2017-06-22 | 2020-05-29 | 陕西师范大学 | 喹唑啉衍生物及其在制备抗肿瘤药物中的应用 |
CN111492245A (zh) | 2017-07-21 | 2020-08-04 | 基因泰克公司 | 癌症的治疗和诊断方法 |
EP3665197A2 (fr) | 2017-08-11 | 2020-06-17 | H. Hoffnabb-La Roche Ag | Anticorps anti-cd8 et utilisations associées |
EP3679159A1 (fr) | 2017-09-08 | 2020-07-15 | H. Hoffnabb-La Roche Ag | Méthodes diagnostiques et thérapeutiques du cancer |
EP3679040B1 (fr) | 2017-09-08 | 2022-08-03 | Amgen Inc. | Inhibiteurs de kras g12c et leurs procédés d'utilisation |
EP3687981A4 (fr) * | 2017-09-26 | 2021-03-31 | The Regents of the University of California | Compositions et méthodes de traitement du cancer |
US11369608B2 (en) | 2017-10-27 | 2022-06-28 | University Of Virginia Patent Foundation | Compounds and methods for regulating, limiting, or inhibiting AVIL expression |
TW201923089A (zh) | 2017-11-06 | 2019-06-16 | 美商建南德克公司 | 癌症之診斷及治療方法 |
JP7254076B2 (ja) | 2017-11-19 | 2023-04-07 | サンシャイン・レイク・ファーマ・カンパニー・リミテッド | 置換ヘテロアリール化合物及び使用方法 |
AU2019209960B2 (en) | 2018-01-20 | 2023-11-23 | Sunshine Lake Pharma Co., Ltd. | Substituted aminopyrimidine compounds and methods of use |
WO2019148036A1 (fr) | 2018-01-26 | 2019-08-01 | Exelixis, Inc. | Composés destinés au traitement des troubles kinases-dépendants |
CN117624045A (zh) | 2018-01-26 | 2024-03-01 | 埃克塞里艾克西斯公司 | 用于治疗激酶依赖性病症的化合物 |
AU2019212800B2 (en) | 2018-01-26 | 2024-05-23 | Exelixis, Inc. | Compounds for the treatment of kinase-dependent disorders |
TWI660728B (zh) * | 2018-02-09 | 2019-06-01 | 國立交通大學 | 胺基喹唑啉衍生物及其醫藥組合物與用途 |
WO2019165434A1 (fr) | 2018-02-26 | 2019-08-29 | Genentech, Inc. | Dosage pour traitement avec des anticorps antagonistes anti-tigit et anti-pd-l1 |
WO2019213526A1 (fr) | 2018-05-04 | 2019-11-07 | Amgen Inc. | Inhibiteurs de kras g12c et leurs procédés d'utilisation |
EP3788038B1 (fr) | 2018-05-04 | 2023-10-11 | Amgen Inc. | Inhibiteurs de kras g12c et leurs procédés d'utilisation |
AU2019265822B2 (en) | 2018-05-10 | 2024-07-18 | Amgen Inc. | KRAS G12C inhibitors for the treatment of cancer |
AU2019275404A1 (en) | 2018-05-21 | 2020-12-03 | Bruker Spatial Biology, Inc. | Molecular gene signatures and methods of using same |
AU2019278998B2 (en) | 2018-06-01 | 2023-11-09 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
MA52780A (fr) | 2018-06-11 | 2021-04-14 | Amgen Inc | Inhibiteurs de kras g12c pour le traitement du cancer |
JP7369719B2 (ja) | 2018-06-12 | 2023-10-26 | アムジエン・インコーポレーテツド | KRas G12C阻害剤及びそれを使用する方法 |
KR20210024550A (ko) | 2018-06-23 | 2021-03-05 | 제넨테크, 인크. | Pd-1 축 결합 길항제, 백금 제제, 및 토포이소머라제 ii 억제제를 이용한 폐암 치료 방법 |
US11203645B2 (en) | 2018-06-27 | 2021-12-21 | Obi Pharma, Inc. | Glycosynthase variants for glycoprotein engineering and methods of use |
CN110642796B (zh) * | 2018-06-27 | 2023-03-17 | 烟台药物研究所 | 一种喹唑啉类衍生物及其应用 |
CN112839644A (zh) | 2018-07-18 | 2021-05-25 | 豪夫迈·罗氏有限公司 | 用pd-1轴结合拮抗剂、抗代谢物和铂剂治疗肺癌的方法 |
CN112805267B (zh) | 2018-09-03 | 2024-03-08 | 豪夫迈·罗氏有限公司 | 用作tead调节剂的甲酰胺和磺酰胺衍生物 |
AU2019342099A1 (en) | 2018-09-19 | 2021-04-08 | Genentech, Inc. | Therapeutic and diagnostic methods for bladder cancer |
CA3111809A1 (fr) | 2018-09-21 | 2020-03-26 | Genentech, Inc. | Procedes de diagnotic pour le cancer du sein triple negatif |
KR20210137422A (ko) | 2018-09-25 | 2021-11-17 | 블랙 다이아몬드 테라퓨틱스, 인코포레이티드 | 티로신 키나아제 억제제로서의 퀴나졸린 유도체, 조성물, 이들의 제조 방법 및 이들의 용도 |
CA3115038A1 (fr) | 2018-10-04 | 2020-04-09 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Inhibiteurs de l'egfr pour traiter les keratodermies |
JP2022512744A (ja) | 2018-10-18 | 2022-02-07 | ジェネンテック, インコーポレイテッド | 肉腫様腎臓がんのための診断および治療方法 |
JP7516029B2 (ja) | 2018-11-16 | 2024-07-16 | アムジエン・インコーポレーテツド | Kras g12c阻害剤化合物の重要な中間体の改良合成法 |
MX2021005700A (es) | 2018-11-19 | 2021-07-07 | Amgen Inc | Inhibidores de kras g12c y metodos de uso de los mismos. |
JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法 |
EP3898592A1 (fr) | 2018-12-20 | 2021-10-27 | Amgen Inc. | Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a |
MA54550A (fr) | 2018-12-20 | 2022-03-30 | Amgen Inc | Inhibiteurs de kif18a |
CA3123227A1 (fr) | 2018-12-20 | 2020-06-25 | Amgen Inc. | Amides d'heteroaryle utiles en tant qu'inhibiteurs de kif18a |
MA54543A (fr) | 2018-12-20 | 2022-03-30 | Amgen Inc | Inhibiteurs de kif18a |
EP3903828A4 (fr) | 2018-12-21 | 2022-10-05 | Daiichi Sankyo Company, Limited | Combinaison d'un conjugué anticorps-médicament et d'un inhibiteur de kinase |
EP3921443A1 (fr) | 2019-02-08 | 2021-12-15 | F. Hoffmann-La Roche AG | Méthodes diagnostiques et thérapeutiques pour le cancer |
CN113710706A (zh) | 2019-02-27 | 2021-11-26 | 豪夫迈·罗氏有限公司 | 用于抗tigit抗体和抗cd20抗体或抗cd38抗体治疗的给药 |
CA3131268A1 (fr) | 2019-02-27 | 2020-09-03 | Epiaxis Therapeutics Pty Ltd | Procedes et agents pour evaluer une fonction de lymphocyte t et predire une reponse a une therapie |
CN113727758A (zh) | 2019-03-01 | 2021-11-30 | 锐新医药公司 | 双环杂环基化合物及其用途 |
US20230148450A9 (en) | 2019-03-01 | 2023-05-11 | Revolution Medicines, Inc. | Bicyclic heteroaryl compounds and uses thereof |
WO2020223233A1 (fr) | 2019-04-30 | 2020-11-05 | Genentech, Inc. | Méthodes pronostiques et thérapeutiques contre le cancer colorectal |
WO2020226986A2 (fr) | 2019-05-03 | 2020-11-12 | Genentech, Inc. | Méthodes de traitement de cancer au moyen d'un anticorps anti-pd-l1 |
EP3738593A1 (fr) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosage d'inhibiteur de kras pour le traitement de cancers |
CA3140392A1 (fr) | 2019-05-21 | 2020-11-26 | Amgen Inc. | Formes a l'etat solide |
CN112300279A (zh) | 2019-07-26 | 2021-02-02 | 上海复宏汉霖生物技术股份有限公司 | 针对抗cd73抗体和变体的方法和组合物 |
CN114401953A (zh) | 2019-08-02 | 2022-04-26 | 美国安进公司 | Kif18a抑制剂 |
MX2022001181A (es) | 2019-08-02 | 2022-02-22 | Amgen Inc | Inhibidores de kif18a. |
CA3146693A1 (fr) | 2019-08-02 | 2021-02-11 | Amgen Inc. | Inhibiteurs de kif18a |
CA3147276A1 (fr) | 2019-08-02 | 2021-02-11 | Amgen Inc. | Inhibiteurs de kif18a |
AU2020341458A1 (en) | 2019-09-04 | 2022-04-21 | Genentech, Inc. | CD8 binding agents and uses thereof |
JP2022551422A (ja) | 2019-09-26 | 2022-12-09 | エグゼリクシス, インコーポレイテッド | ピリドン化合物およびタンパク質キナーゼの調節における使用の方法 |
PE20221110A1 (es) | 2019-09-27 | 2022-07-11 | Genentech Inc | Administracion de dosis para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1 |
MX2022004656A (es) | 2019-10-24 | 2022-05-25 | Amgen Inc | Derivados de piridopirimidina utiles como inhibidores de kras g12c y kras g12d en el tratamiento del cancer. |
CN114728936A (zh) | 2019-10-29 | 2022-07-08 | 豪夫迈·罗氏有限公司 | 用于治疗癌症的双功能化合物 |
MX2022005360A (es) | 2019-11-04 | 2022-06-02 | Revolution Medicines Inc | Inhibidores de ras. |
JP2022553858A (ja) | 2019-11-04 | 2022-12-26 | レボリューション メディシンズ インコーポレイテッド | Ras阻害剤 |
CR20220240A (es) | 2019-11-04 | 2022-08-03 | Revolution Medicines Inc | Inhibidores de ras |
EP4055388A1 (fr) | 2019-11-06 | 2022-09-14 | Genentech, Inc. | Méthodes diagnostiques et thérapeutiques pour le traitement de cancers hématologiques |
BR112022008858A2 (pt) | 2019-11-08 | 2022-09-06 | Revolution Medicines Inc | Composto, composição farmacêutica e métodos para inibir sos1 em um sujeito, para inibir a interação de sos1 e uma proteína, para tratar ou prevenir uma doença e para tratar ou prevenir câncer |
US20210161897A1 (en) | 2019-11-12 | 2021-06-03 | Astrazeneca Ab | Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
AU2020381458A1 (en) | 2019-11-13 | 2022-05-12 | Genentech, Inc. | Therapeutic compounds and methods of use |
TW202132271A (zh) | 2019-11-14 | 2021-09-01 | 美商安進公司 | Kras g12c抑制劑化合物之改善的合成 |
JP2023501528A (ja) | 2019-11-14 | 2023-01-18 | アムジエン・インコーポレーテツド | Kras g12c阻害剤化合物の改善された合成 |
CN114980976A (zh) | 2019-11-27 | 2022-08-30 | 锐新医药公司 | 共价ras抑制剂及其用途 |
PE20221511A1 (es) | 2019-12-13 | 2022-10-04 | Genentech Inc | Anticuerpos anti-ly6g6d y metodos de uso |
WO2021127404A1 (fr) | 2019-12-20 | 2021-06-24 | Erasca, Inc. | Pyridones et pyrimidones tricycliques |
KR20220124768A (ko) | 2020-01-07 | 2022-09-14 | 레볼루션 메디슨즈, 인크. | Shp2 억제제 투여 및 암 치료방법 |
KR20220130190A (ko) | 2020-01-20 | 2022-09-26 | 아스트라제네카 아베 | 암 치료를 위한 표피성장인자 수용체 티로신 키나제 억제제 |
MX2022009170A (es) | 2020-01-27 | 2022-08-17 | Genentech Inc | Procedimientos para el tratamiento del cancer con un anticuerpo antagonista anti-tigit. |
WO2022050954A1 (fr) | 2020-09-04 | 2022-03-10 | Genentech, Inc. | Dosage pour traitement avec anticorps antagonistes anti-tigit et anti-pd-l1 |
WO2021194481A1 (fr) | 2020-03-24 | 2021-09-30 | Genentech, Inc. | Dosage pour le traitement avec des anticorps antagonistes anti-tigit et anti-pd-l1 |
WO2021177980A1 (fr) | 2020-03-06 | 2021-09-10 | Genentech, Inc. | Polythérapie contre le cancer comprenant un antagoniste de liaison à l'axe pd-1 et un antagoniste de l'il 6 |
CN115698717A (zh) | 2020-04-03 | 2023-02-03 | 基因泰克公司 | 癌症的治疗和诊断方法 |
CN115885050A (zh) | 2020-04-28 | 2023-03-31 | 基因泰克公司 | 用于非小细胞肺癌免疫疗法的方法和组合物 |
MX2022015877A (es) | 2020-06-16 | 2023-01-24 | Genentech Inc | Metodos y composiciones para tratar cancer de mama triple negativo. |
AU2021293507A1 (en) | 2020-06-18 | 2023-02-02 | F. Hoffmann-La Roche Ag | Treatment with anti-TIGIT antibodies and PD-1 axis binding antagonists |
KR20230042600A (ko) | 2020-06-18 | 2023-03-28 | 레볼루션 메디슨즈, 인크. | Ras 억제제에 대한 획득된 저항성을 지연, 예방, 및 치료하는 방법 |
WO2022002874A1 (fr) | 2020-06-30 | 2022-01-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Procédés pour prédire le risque de récidive et/ou de mort de patients souffrant d'un cancer solide après un traitement adjuvant préopératoire et une chirurgie radicale |
EP4172621A1 (fr) | 2020-06-30 | 2023-05-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Procédés pour prédire le risque de récidive et/ou de mort de patients souffrant d'un cancer solide après des traitements adjuvants pré-opératoires |
US11787775B2 (en) | 2020-07-24 | 2023-10-17 | Genentech, Inc. | Therapeutic compounds and methods of use |
EP4189121A1 (fr) | 2020-08-03 | 2023-06-07 | Genentech, Inc. | Méthodes diagnostiques et thérapeutiques pour le lymphome |
WO2022036146A1 (fr) | 2020-08-12 | 2022-02-17 | Genentech, Inc. | Méthodes diagnostiques et thérapeutiques pour le cancer |
IL300930A (en) | 2020-08-27 | 2023-04-01 | Enosi Therapeutics Corp | Methods and compositions for the treatment of autoimmune diseases and cancer |
KR20230081726A (ko) | 2020-09-03 | 2023-06-07 | 레볼루션 메디슨즈, 인크. | Shp2 돌연변이가 있는 악성 종양을 치료하기 위한 sos1 억제제의 용도 |
JP2023541916A (ja) | 2020-09-15 | 2023-10-04 | レボリューション メディシンズ インコーポレイテッド | がんの治療における、ras阻害剤としてのインドール誘導体 |
MX2023003338A (es) | 2020-09-23 | 2023-06-14 | Erasca Inc | Piridonas y pirimidonas tricíclicas. |
MX2023003756A (es) | 2020-10-05 | 2023-04-24 | Genentech Inc | Dosis para el tratamiento con anticuerpos biespecificos anti-fcrh5/anti-cd3. |
WO2022133345A1 (fr) | 2020-12-18 | 2022-06-23 | Erasca, Inc. | Pyridones et pyrimidones tricycliques |
CA3203111A1 (fr) | 2020-12-22 | 2022-06-30 | Kailiang Wang | Inhibiteurs de sos1 et utilisations associees |
KR20230146052A (ko) | 2021-02-12 | 2023-10-18 | 에프. 호프만-라 로슈 아게 | 암 치료용 비시클릭 테트라히드로아제핀 유도체 |
WO2022178205A1 (fr) | 2021-02-19 | 2022-08-25 | Exelixis, Inc. | Composés de pyridone et leurs procédés d'utilisation |
PE20240089A1 (es) | 2021-05-05 | 2024-01-16 | Revolution Medicines Inc | Inhibidores de ras para el tratamiento del cancer |
EP4334321A1 (fr) | 2021-05-05 | 2024-03-13 | Revolution Medicines, Inc. | Inhibiteurs de ras |
CN117500811A (zh) | 2021-05-05 | 2024-02-02 | 锐新医药公司 | 共价ras抑制剂及其用途 |
CA3221390A1 (fr) | 2021-05-25 | 2022-12-01 | Erasca, Inc. | Inhibiteurs de kras tricycliques heteroaromatiques contenant du soufre |
WO2022266206A1 (fr) | 2021-06-16 | 2022-12-22 | Erasca, Inc. | Conjugués d'inhibiteurs de kras |
WO2023001894A1 (fr) | 2021-07-20 | 2023-01-26 | Ags Therapeutics Sas | Vésicules extracellulaires provenant de microalgues, leur préparation et leurs utilisations |
TW202321261A (zh) | 2021-08-10 | 2023-06-01 | 美商伊瑞斯卡公司 | 選擇性kras抑制劑 |
AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
US20230202984A1 (en) | 2021-11-24 | 2023-06-29 | Genentech, Inc. | Therapeutic compounds and methods of use |
US20230203062A1 (en) | 2021-11-24 | 2023-06-29 | Genentech, Inc. | Therapeutic compounds and methods of use |
WO2023114954A1 (fr) | 2021-12-17 | 2023-06-22 | Genzyme Corporation | Composés pyrazolopyrazine utilisés comme inhibiteurs de la shp2 |
WO2023144127A1 (fr) | 2022-01-31 | 2023-08-03 | Ags Therapeutics Sas | Vésicules extracellulaires provenant de microalgues, leur biodistribution suite à leur administration, et leurs utilisations |
EP4227307A1 (fr) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Composés pyrazolopyrazine en tant qu'inhibiteurs de shp2 |
WO2023172940A1 (fr) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Méthodes de traitement du cancer du poumon réfractaire immunitaire |
WO2023187037A1 (fr) | 2022-03-31 | 2023-10-05 | Astrazeneca Ab | Inhibiteurs de tyrosine kinase du récepteur du facteur de croissance épidermique (egfr) en combinaison avec un inhibiteur d'akt pour le traitement du cancer |
WO2023191816A1 (fr) | 2022-04-01 | 2023-10-05 | Genentech, Inc. | Dosage pour traitement avec des anticorps bispécifiques anti-fcrh5/anti-cd3 |
WO2023219613A1 (fr) | 2022-05-11 | 2023-11-16 | Genentech, Inc. | Dosage pour le traitement avec des anticorps bispécifiques anti-fcrh5/anti-cd3 |
WO2023240058A2 (fr) | 2022-06-07 | 2023-12-14 | Genentech, Inc. | Méthodes pronostiques et thérapeutiques pour le cancer |
WO2023240263A1 (fr) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Inhibiteurs de ras macrocycliques |
WO2024002938A1 (fr) | 2022-06-27 | 2024-01-04 | Astrazeneca Ab | Combinaisons impliquant des inhibiteurs de tyrosine kinase du récepteur du facteur de croissance épidermique pour traiter le cancer |
WO2024015897A1 (fr) | 2022-07-13 | 2024-01-18 | Genentech, Inc. | Dosage pour traitement avec anticorps bispécifiques anti-fcrh5/anti-cd3 |
WO2024020432A1 (fr) | 2022-07-19 | 2024-01-25 | Genentech, Inc. | Dosage pour traitement avec des anticorps bispécifiques anti-fcrh5/anti-cd3 |
WO2024033389A1 (fr) | 2022-08-11 | 2024-02-15 | F. Hoffmann-La Roche Ag | Dérivés bicycliques de tétrahydrothiazépine |
WO2024033388A1 (fr) | 2022-08-11 | 2024-02-15 | F. Hoffmann-La Roche Ag | Dérivés bicycliques de tétrahydrothiazépine |
WO2024033457A1 (fr) | 2022-08-11 | 2024-02-15 | F. Hoffmann-La Roche Ag | Dérivés bicycliques de tétrahydrothiazépine |
WO2024033458A1 (fr) | 2022-08-11 | 2024-02-15 | F. Hoffmann-La Roche Ag | Dérivés bicycliques de tétrahydroazépine |
WO2024081916A1 (fr) | 2022-10-14 | 2024-04-18 | Black Diamond Therapeutics, Inc. | Méthodes de traitement de cancers à l'aide de dérivés d'isoquinoline ou de 6-aza-quinoléine |
WO2024085242A2 (fr) | 2022-10-21 | 2024-04-25 | Kawasaki Institute Of Industrial Promotion | Vésicule anti-encrassement ou super furtive |
WO2024088808A1 (fr) | 2022-10-24 | 2024-05-02 | Ags Therapeutics Sas | Vésicules extracellulaires provenant de microalgues, leur biodistribution lors d'une administration intranasale, et leurs utilisations |
WO2024091991A1 (fr) | 2022-10-25 | 2024-05-02 | Genentech, Inc. | Méthodes thérapeutiques et diagnostiques pour myélomes multiples |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SU400048A1 (fr) * | 1970-12-14 | 1973-10-03 | ||
SU466233A1 (ru) * | 1973-06-08 | 1975-04-05 | Всесоюзный научно-исследовательский химико-фармацевтический институт им. С.Орджоникидзе | Способ получени производных 2-метил-4-диалкиламиноалкиламинохиназолина |
US5710158A (en) * | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
CA2102780C (fr) | 1991-05-10 | 2007-01-09 | Alfred P. Spada | Composes de type bis-monoaryle, aryle bicyclique et (ou) heteroaryle inhibant l'activite de tyrosine kinase des recepteurs de l'egf et (ou) du pdgf |
NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
GB9300059D0 (en) | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
US5258518A (en) * | 1992-04-01 | 1993-11-02 | G. D. Searle & Co. | 2-substituted tertiary carbinol derivatives of deoxynojirimycin |
GB9323290D0 (en) | 1992-12-10 | 1994-01-05 | Zeneca Ltd | Quinazoline derivatives |
GB9314884D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Tricyclic derivatives |
GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
-
1995
- 1995-06-06 EP EP95918713A patent/EP0817775B1/fr not_active Expired - Lifetime
- 1995-06-06 DE DE69522717T patent/DE69522717T2/de not_active Expired - Lifetime
- 1995-06-06 EP EP10186213A patent/EP2295415A1/fr not_active Ceased
- 1995-06-06 EP EP01104696A patent/EP1110953B1/fr not_active Expired - Lifetime
- 1995-06-06 WO PCT/IB1995/000436 patent/WO1996030347A1/fr active IP Right Grant
- 1995-06-06 EP EP09174228.8A patent/EP2163546B1/fr not_active Expired - Lifetime
- 1995-06-06 DE DE200512000053 patent/DE122005000053I2/de active Active
- 1995-06-06 AT AT01104696T patent/ATE446955T1/de not_active IP Right Cessation
- 1995-06-06 ES ES95918713T patent/ES2161290T3/es not_active Expired - Lifetime
- 1995-06-06 DK DK95918713T patent/DK0817775T3/da active
- 1995-06-06 CA CA002216796A patent/CA2216796C/fr not_active Expired - Lifetime
- 1995-06-06 AT AT95918713T patent/ATE205483T1/de active
- 1995-06-06 JP JP08529113A patent/JP3088018B2/ja not_active Expired - Lifetime
- 1995-06-06 DE DE69536015T patent/DE69536015D1/de not_active Expired - Lifetime
- 1995-06-06 PT PT95918713T patent/PT817775E/pt unknown
- 1995-06-06 EP EP16171536.2A patent/EP3103799B1/fr not_active Expired - Lifetime
- 1995-06-06 MX MX9707453A patent/MX9707453A/es active IP Right Grant
- 1995-06-06 ES ES01104696T patent/ES2332984T3/es not_active Expired - Lifetime
-
1996
- 1996-03-05 TW TW085102699A patent/TW454000B/zh not_active IP Right Cessation
- 1996-03-07 AP APAP/P/1996/000788A patent/AP735A/en active
- 1996-03-21 IL IL11759896A patent/IL117598A/xx active Protection Beyond IP Right Term
- 1996-03-21 IL IL12999596A patent/IL129995A/xx not_active IP Right Cessation
- 1996-03-21 IL IL129994A patent/IL129994A/en not_active IP Right Cessation
- 1996-03-21 IL IL189037A patent/IL189037A/en not_active IP Right Cessation
- 1996-03-25 MA MA24190A patent/MA23831A1/fr unknown
- 1996-03-25 SK SK56-2003A patent/SK283763B6/sk not_active IP Right Cessation
- 1996-03-25 SK SK387-96A patent/SK283762B6/sk not_active IP Right Cessation
- 1996-03-25 AR ARP960101903A patent/AR002723A1/es active IP Right Grant
- 1996-03-25 PE PE1996000207A patent/PE43897A1/es not_active IP Right Cessation
- 1996-03-27 NZ NZ286263A patent/NZ286263A/en not_active IP Right Cessation
- 1996-03-28 EG EG26996A patent/EG24229A/xx active
- 1996-03-28 UA UA96031214A patent/UA44254C2/uk unknown
- 1996-03-28 CN CN96102992A patent/CN1066142C/zh not_active Expired - Lifetime
- 1996-03-29 RU RU0096106055A patent/RU2694252C3/ru active IP Right Grant
- 1996-03-29 SG SG1996006639A patent/SG43262A1/en unknown
- 1996-03-29 CZ CZ1996931A patent/CZ294967B6/cs not_active IP Right Cessation
- 1996-03-29 HU HU9600834A patent/HU229120B1/hu active Protection Beyond IP Right Term
- 1996-03-29 ZA ZA9602522A patent/ZA962522B/xx unknown
- 1996-03-29 CZ CZ19972067A patent/CZ295145B6/cs not_active IP Right Cessation
- 1996-03-29 TR TR96/00265A patent/TR199600265A1/xx unknown
- 1996-03-29 OA OA60807A patent/OA10277A/en unknown
- 1996-03-29 HR HR960147A patent/HRP960147B1/xx not_active IP Right Cessation
- 1996-03-29 RU RU0096106055K patent/RU2694252C2/ru active Protection Beyond IP Right Term
- 1996-03-29 SI SI9600102A patent/SI9600102A/sl active Search and Examination
- 1996-03-29 NO NO961299A patent/NO308740B1/no not_active IP Right Cessation
- 1996-03-29 CO CO96015833A patent/CO4410333A1/es unknown
- 1996-03-29 AU AU50406/96A patent/AU703638B2/en not_active Expired
- 1996-03-29 BR BRPI9601200-5A patent/BR9601200B1/pt not_active IP Right Cessation
- 1996-03-29 MY MYPI96001194A patent/MY117896A/en unknown
- 1996-03-30 KR KR1019960009659A patent/KR100232335B1/ko active IP Right Grant
- 1996-03-30 SA SA96160707A patent/SA96160707B1/ar unknown
-
1997
- 1997-09-29 FI FI973832A patent/FI120646B/fi not_active IP Right Cessation
- 1997-09-29 PL PL96313541A patent/PL186843B1/pl unknown
-
1999
- 1999-05-17 IL IL12999499A patent/IL129994A0/xx active IP Right Grant
- 1999-05-17 IL IL12999599A patent/IL129995A0/xx unknown
- 1999-05-17 IL IL12999699A patent/IL129996A0/xx unknown
- 1999-06-23 AU AU35854/99A patent/AU3585499A/en not_active Abandoned
-
2001
- 2001-10-30 GR GR20010401942T patent/GR3037070T3/el unknown
- 2001-12-24 HK HK01109050.7A patent/HK1038740A1/xx not_active IP Right Cessation
-
2005
- 2005-12-14 LU LU91209C patent/LU91209I2/fr unknown
-
2006
- 2006-01-02 NL NL300214C patent/NL300214I2/nl unknown
- 2006-03-06 NO NO2006004C patent/NO2006004I2/no unknown
- 2006-03-15 FR FR06C0010C patent/FR06C0010I2/fr active Active
-
2014
- 2014-01-21 HU HUS1400001C patent/HUS1400001I1/hu unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO308740B1 (no) | Kinazolinderivater, anvendelse derav og farmasøytisk blanding | |
NO308298B1 (no) | Substituerte kinazolinderivater, anvendelse derav og farmasøytiske preparater inneholdende dem | |
EE03482B1 (et) | Kinasoliiniderivaadid, nende valmistamismeetod ja kasutamine | |
NO307513B1 (no) | 2,8-disubstituert chinazolinon og anvendelse derav | |
DK0826673T3 (da) | Acetamidderivater, fremgangsmåde til fremstilling deraf og medicinske præparater | |
IS3720A7 (is) | Afleiður dialkoxy-pyridinyl-benzimidazole, aðferðvið lögun þeirra og lyfjafræðileg notkun | |
NO307092B1 (no) | Sordaridin-derivater, anvendelse derav og farmasoeytisk blanding | |
DK0871656T3 (da) | Dolastatinderivater, deres fremstilling og anvendelse | |
NO305952B1 (no) | 1,5-benzodiazepinderivater, anvendelse derav og farmasoeytiske preparater | |
IS4345A (is) | Setin N-(indól-2-karbónýl)-b-alaninamíð, notkun þeirra og lyfjaefnablöndur | |
NO306253B1 (no) | Arylsulfonyl-hydroksamsyre-derivater, anvendelse derav og farmasöytisk preparat | |
NO943511D0 (no) | Farmasöytiske preparater og anvendelse derav | |
NO943682D0 (no) | Imidazol-4-yl-piperidin-derivater, deres fremstilling og terapeutiske anvendelse | |
NO973288D0 (no) | Blanding og anvendelse | |
NO951447D0 (no) | Organoaluminoksyprodukt, fremstilling og anvendelse | |
NO953673D0 (no) | [1,2,4ÅTriazolo[4,3-aÅkinoksalinderivater, deres fremstilling og anvendelse | |
DK1025100T3 (da) | 3-substituerede tetrahydropyridopyrimidinonderivater, fremstilling og anvendelsen heraf | |
NO962477L (no) | Benzamidderivater, deres fremstilling og deres terapautiske anvendelse | |
ATE252096T1 (de) | Prolylendopeptidase-inhibitoren, ihre herstellung und ihre pharmazeutische verwendung | |
DK0675133T3 (da) | 13-Substituerede milbemycinderivater, fremstilling deraf og anvendelse deraf | |
NO973980D0 (no) | Imiadazolderivater og medisinsk preparat | |
NO980471L (no) | Benzensulfonamidderivater, fremstilling derav og terapautiske anvendelser derav | |
NO981002D0 (no) | Karboksylsyrederivater, deres fremstilling og anvendelse | |
NO20000066D0 (no) | 6-pyrrolidin-2-ylpyrindin-derivater, deres fremstilling og deres farmasoeytiske anvendelse | |
NO982549D0 (no) | 5-naftalen-1-yl-1,3-dioksan-derivater, fremstilling og terapeutisk anvendelse derav |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
SPCF | Filing of supplementary protection certificate |
Free format text: PRODUCT NAME: TARCEVA-ERLOTINIB; NAT. REG. NO/DATE: EU/1/05/311/001/NO 20050919; FIRST REG. NO/DATE: EU , EU/1/05/311/001 20050321 Spc suppl protection certif: 2006004 Filing date: 20060306 |
|
SPCG | Granted supplementary protection certificate |
Free format text: PRODUCT NAME: TARCEVA-ERLOTINIB; NAT. REG. NO/DATE: EU/1/05/311/001/NO 20050919; FIRST REG. NO/DATE: EU , EU/1/05/311/001 20050321 Spc suppl protection certif: 2006004 Filing date: 20060306 Extension date: 20200321 |
|
CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: OSI PHARMACEUTICALS LLC, US |
|
MK1K | Patent expired | ||
SPCX | Expiry of an spc |
Spc suppl protection certif: 2006004 Effective date: 20200406 |